Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy

The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases

Lilly to buy Ventyx Biosciences for $1.2 billion

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation

ABL Bio secures $55 million from Eli Lilly to accelerate Grabody platform development

The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas

Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry

Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions

Eli Lilly to unveil major breast cancer data at SABCS 2025

Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival

Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025

Jaypirca is making waves in the fight against B-cell malignancies

Lilly expands biotech footprint with new Gateway Labs in Philadelphia

The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies

Eli Lilly to invest $1.2 billion in Puerto Rico to boost U.S. oral medicine production

Lilly to build $3 billion oral medicine facility in Netherlands

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain

Lilly’s Omvoh shows rapid and lasting relief from bowel urgency in ulcerative colitis patients